Novartis (NVS)

74.15 -0.86  -1.15%  May 17, 8:00PM
Add to Watchlists Create an Alert

Novartis R&D Expense Quarterly:

2.297B for March 31, 2013
View Full Chart

Novartis R&D Expense Quarterly Chart

    Novartis Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 2   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    March 31, 2013 2.297B
    Dec. 31, 2012 2.621B
    Sept. 30, 2012 2.191B
    June 30, 2012 2.285B
    March 31, 2012 2.235B
    Dec. 31, 2011 2.523B
    Sept. 30, 2011 2.475B
    June 30, 2011 2.397B
    March 31, 2011 2.188B
    Dec. 31, 2010 2.592B
    Sept. 30, 2010 2.548B
    June 30, 2010 1.893B
    March 31, 2010 2.037B
    Dec. 31, 2009 2.148B
    Sept. 30, 2009 1.825B
    June 30, 2009 1.802B
    March 31, 2009 1.694B
    Dec. 31, 2008 1.834B
    Sept. 30, 2008 1.942B
    June 30, 2008 1.767B
    March 31, 2008 Go Pro
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro
    June 30, 2007 Go Pro
    March 31, 2007 Go Pro
       
    Dec. 31, 2006 Go Pro
    Sept. 30, 2006 Go Pro
    June 30, 2006 Go Pro
    March 31, 2006 Go Pro
    Dec. 31, 2005 Go Pro
    Sept. 30, 2005 Go Pro
    June 30, 2005 Go Pro
    March 31, 2005 Go Pro
    Dec. 31, 2004 Go Pro
    Sept. 30, 2004 Go Pro
    June 30, 2004 Go Pro
    March 31, 2004 Go Pro
    Dec. 31, 2003 Go Pro
    Sept. 30, 2003 Go Pro
    June 30, 2003 Go Pro
    March 31, 2003 Go Pro
    Dec. 31, 2002 Go Pro
    Sept. 30, 2002 Go Pro
    June 30, 2002 Go Pro
    March 31, 2002 Go Pro
    Dec. 31, 2001 Go Pro
    Sept. 30, 2001 Go Pro
    June 30, 2001 Go Pro
    March 31, 2001 Go Pro
    Dec. 31, 2000 Go Pro

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    NVS R&D Expense Quarterly Benchmarks

    Companies
    Pfizer 1.80B
    Sanofi 1.480B
    Merck 1.907B

    NVS R&D Expense Quarterly Rankings

    Overall 99th percentile
    3 of 7590
    Sector 99th percentile
    1 of 651 in Healthcare
    Industry 98th percentile
    1 of 52 in Drug Manufacturers - Major

    NVS R&D Expense Quarterly Range, Past 5 Years

    Minimum 1.694B Mar 2009
    Maximum 2.621B Dec 2012
    Average 2.165B